SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to determine the efficacy of oral SCIO-469 in patients with rheumatoid arthritis who are not receiving liver damaging (hepatotoxic) disease-modifying anti-rheumatic drugs (DMARDs).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Scios, Inc.
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

• Patients having active rheumatoid arthritis who are not receiving medications known as hepatotoxic disease-modifying anti-rheumatic drugs (DMARDs)

• Patients taking hydroxychloroquine (Plaquenil) must be on a stable or consistent dose prior to entering study

Exclusion Criteria:

• Patients using Enbrel, Remicade, Kineret, Humira, or an experimental biologic agent within the past 3 months

• Lab tests revealed elevated liver enzymes within the past 6 months

• Medical history of Tuberculosis, cancer, multiple sclerosis, neuropathy or encephalopathy

• HIV positive

• Abnormal electrocardiogram

• Chronic or acute infection